{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:12:51Z","timestamp":1780341171899,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000655","name":"Marine Biological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019708","name":"UroGen Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102392","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T02:48:39Z","timestamp":1750819719000},"page":"102392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Kent","family":"Chevli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Saltzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-8986","authenticated-orcid":false,"given":"Michael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3106-6173","authenticated-orcid":false,"given":"Andrew","family":"Meads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102392_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102392_bib0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-018-2438-9","article-title":"ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer","volume":"37","author":"Monteiro","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102392_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/CU9.0000000000000160","article-title":"A retrospective analysis of the factors associated with increased risk of readmission within 30 days after primary transurethral resection of bladder tumor","volume":"17","author":"Jindal","year":"2023","journal-title":"Curr Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2018.10.027","article-title":"The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement","volume":"125","author":"Pereira","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102392_bib0007","series-title":"American Society of Clinical Oncology Genitourinary Cancers Symposium","first-page":"742","article-title":"Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database","volume":"43 (suppl 5, abstr 1)","author":"Doshi","year":"2025"},{"key":"10.1016\/j.clgc.2025.102392_bib0008","doi-asserted-by":"crossref","first-page":"498.e491","DOI":"10.1016\/j.urolonc.2018.08.004","article-title":"Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence","volume":"36","author":"Yap","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102392_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0602","article-title":"Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial","volume":"5","author":"Lewicki","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.clgc.2025.102392_bib0010","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.4111\/icu.2016.57.S1.S4","article-title":"Active surveillance for nonmuscle invasive bladder cancer","volume":"57","author":"Miyake","year":"2016","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0012","first-page":"16","article-title":"A Systematic Review of the Use of Surgical Checklists in Transurethral Resection of Bladder Tumour","author":"Botros","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102392_bib0013","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2025.102392_bib0014","article-title":"Pharmacokinetics of UGN\u2011102, a mitomycin\u2011containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer","author":"Prasad","year":"2025","journal-title":"In press"},{"key":"10.1016\/j.clgc.2025.102392_bib0015","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000004511","article-title":"Perceived Impact on Patient Routines\/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial","author":"Stover","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0016","first-page":"e95","article-title":"Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3b Trial","volume":"4","author":"Morris","year":"2025","journal-title":"Rev Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0017","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/JU.0000000000002747","article-title":"Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer","volume":"208","author":"Stover","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0019","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.15209","article-title":"Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification","volume":"127","author":"Kohada","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102392_bib0021","first-page":"123","article-title":"Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial","volume":"20","author":"Ansari Djafari","year":"2023","journal-title":"Urol J"},{"key":"10.1016\/j.clgc.2025.102392_bib0022","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0023","first-page":"47","article-title":"Adjuvant Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer","volume":"40","author":"Dr\u0103goescu","year":"2014","journal-title":"Curr Health Sci J"},{"key":"10.1016\/j.clgc.2025.102392_bib0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2340\/sju.v58.10160","article-title":"Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy","volume":"58","author":"Hoogeveen","year":"2023","journal-title":"Scand J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2016.03.053","volume":"70","author":"Naito","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0026","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2022.08.012","volume":"83","author":"Pedersen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0027","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2022.12.009","article-title":"Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort","volume":"173","author":"Sharma","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102392_bib0028","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2024.08.001","article-title":"Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG)","volume":"8","author":"Contieri","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102392_bib0029","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/bju.16269","article-title":"Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer","volume":"133","author":"Vitug","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102392_bib0031","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 +\/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0032","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)","volume":"213","author":"Prasad","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102392_bib0033","series-title":"In ASCO","first-page":"398","article-title":"Duration of response (DOR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18 month DOR data from the phase 3 ENVISION trial","author":"Prasad","year":"2025"},{"key":"10.1016\/j.clgc.2025.102392_bib0034","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/JU.0000000000002941","article-title":"Patient and Provider Perception of Transurethral Resection of Bladder Tumor vs Chemoablation for Nonmuscle-invasive Bladder Cancer Treatment","volume":"209","author":"Parisse","year":"2023","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:26:34Z","timestamp":1757517994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1558767325000928"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102392","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102392"}}